Results · Apr-Jun 2026
Anthem Biosciences Q1 FY27 results
Sales fell 23% to ₹418 crore from ₹540 crore in Apr-Jun 2025.
Operating profit fell 21% to ₹151 crore, an operating margin of 36.0% (up 0.6 points from a year ago).
Net profit fell 12% to ₹120 crore from ₹136 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales −32%, net profit −37%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 418.2 | 540.2 | −23% |
| Operating profit (EBITDA) | 150.6 | 191.5 | −21% |
| Operating margin | 36.0% | 35.4% | +0.6 pts |
| Net profit | 119.9 | 135.8 | −12% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 5 quarters
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.